These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32667922)

  • 21. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis.
    Iadevaia S; Lu Y; Morales FC; Mills GB; Ram PT
    Cancer Res; 2010 Sep; 70(17):6704-14. PubMed ID: 20643779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.
    Takashima A; English B; Chen Z; Cao J; Cui R; Williams RM; Faller DV
    ACS Chem Biol; 2014 Apr; 9(4):1003-14. PubMed ID: 24506253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
    Pandey MK; Gowda K; Doi K; Sharma AK; Wang HG; Amin S
    PLoS One; 2013; 8(11):e78570. PubMed ID: 24223823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.
    Lee EF; Harris TJ; Tran S; Evangelista M; Arulananda S; John T; Ramnac C; Hobbs C; Zhu H; Gunasingh G; Segal D; Behren A; Cebon J; Dobrovic A; Mariadason JM; Strasser A; Rohrbeck L; Haass NK; Herold MJ; Fairlie WD
    Cell Death Dis; 2019 Apr; 10(5):342. PubMed ID: 31019203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of integrin β3 signals to reverse the stem-like phenotype and drug resistance in melanoma.
    Zhu X; Tao X; Lu W; Ding Y; Tang Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):615-624. PubMed ID: 30627776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
    Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
    Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.
    Flashner-Abramson E; Klein S; Mullin G; Shoshan E; Song R; Shir A; Langut Y; Bar-Eli M; Reuveni H; Levitzki A
    Oncogene; 2016 May; 35(20):2675-80. PubMed ID: 26119932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.
    Fattore L; Marra E; Pisanu ME; Noto A; de Vitis C; Belleudi F; Aurisicchio L; Mancini R; Torrisi MR; Ascierto PA; Ciliberto G
    J Transl Med; 2013 Jul; 11():180. PubMed ID: 23890105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dehydroleucodine inhibits tumor growth in a preclinical melanoma model by inducing cell cycle arrest, senescence and apoptosis.
    Costantino VV; Lobos-Gonzalez L; Ibañez J; Fernandez D; Cuello-Carrión FD; Valenzuela MA; Barbieri MA; Semino SN; Jahn GA; Quest AF; Lopez LA
    Cancer Lett; 2016 Mar; 372(1):10-23. PubMed ID: 26718258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
    Vergani E; Vallacchi V; Frigerio S; Deho P; Mondellini P; Perego P; Cassinelli G; Lanzi C; Testi MA; Rivoltini L; Bongarzone I; Rodolfo M
    Neoplasia; 2011 Dec; 13(12):1132-42. PubMed ID: 22241959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling.
    Lescarbeau RM; Kaplan DL
    BMC Cancer; 2014 May; 14():325. PubMed ID: 24885093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
    Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP
    Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
    Daphu I; Horn S; Stieber D; Varughese JK; Spriet E; Dale HA; Skaftnesmo KO; Bjerkvig R; Thorsen F
    Int J Mol Sci; 2014 May; 15(5):8773-94. PubMed ID: 24840574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computational modeling in melanoma for novel drug discovery.
    Pennisi M; Russo G; Di Salvatore V; Candido S; Libra M; Pappalardo F
    Expert Opin Drug Discov; 2016 Jun; 11(6):609-21. PubMed ID: 27046143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
    Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
    J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling.
    Flobak Å; Baudot A; Remy E; Thommesen L; Thieffry D; Kuiper M; Lægreid A
    PLoS Comput Biol; 2015 Aug; 11(8):e1004426. PubMed ID: 26317215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies.
    Eduati F; Jaaks P; Wappler J; Cramer T; Merten CA; Garnett MJ; Saez-Rodriguez J
    Mol Syst Biol; 2020 Feb; 16(2):e8664. PubMed ID: 32073727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
    Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.